GLP-1 Weight Management
Access private glp-1 weight management treatments with your trusted NHS doctor
Overview
Clinically supervised options for weight management, including private prescribing and NHS-aligned treatment pathways. Weight management medicines are not suitable for everyone and are intended to support lifestyle changes including nutrition, physical activity, sleep, and behavioural support.
Last updated: May 2026
NHS access and rollout (England)
NHS access to tirzepatide (Mounjaro®) is being introduced in phases because demand is expected to exceed current NHS capacity. Eligibility criteria may change as the rollout expands.
Current NHS rollout (2025-2026)
Patients may currently be considered if they have:
- A BMI of 40 kg/m² or above
- Four or more weight-related health conditions
Examples of qualifying conditions include:
- Type 2 diabetes
- Hypertension
- Dyslipidaemia
- Obstructive sleep apnoea
- Cardiovascular disease
For some ethnic groups, including South Asian, Chinese, other Asian, Middle Eastern, Black African and African-Caribbean backgrounds, lower BMI thresholds may apply.
NHS availability may vary depending on local service capacity and commissioning arrangements.
Private suitability
Private prescribing may be considered where clinically appropriate following medical assessment.
Patients may be suitable if they:
- Are adults (18+)
- Have a BMI of:
- 30 kg/m² or above, or
- 27 kg/m² or above with weight-related health conditions
- Are willing to combine treatment with lifestyle changes
- Have no contraindications identified during assessment
Treatment may not be suitable during:
- Pregnancy or breastfeeding
- Certain endocrine or gastrointestinal conditions
- Previous serious reactions to GLP-1 medicines
- Relevant pancreatic, thyroid, or eating disorder history
Common questionnaire topics
Assessment commonly includes:
- Current weight, height, and BMI
- Weight history and previous treatments
- Existing medical conditions
- Current medicines
- Lifestyle and dietary factors
- Blood pressure and metabolic risk factors
- Previous use of GLP-1 medicines
- Pregnancy and safeguarding screening where relevant
Treatment approach
Weight management medicines are intended to support longer-term health improvement and are usually prescribed alongside:
- Dietary changes
- Physical activity
- Behavioural support
- Ongoing clinical review
Response to treatment, side effects, adherence, and safety are reviewed regularly. Treatment may be adjusted, paused, or stopped depending on clinical response.
Further information
Review Fee
The fixed medical review fee for this indication is £15.00.
This fee covers the independent clinical assessment carried out by your reviewing doctor, including reviewing your medical questionnaire, checking suitability and safety, and making a prescribing decision where appropriate.
The review fee is charged once your request is submitted for clinical assessment and is non-refundable after the review has been completed.
Available Medicines
Available treatment options may include tirzepatide (Mounjaro®), where clinically appropriate following medical assessment.
Each prescription typically includes:
- one (1) pre-filled pen
- containing four (4) weekly doses
- representing approximately four (4) weeks of treatment when used as directed
| tirzepatide | Mounjaro KwikPen | 2.5mg/0.6ml | 1 pen (4 doses) | Self Injection | £154.99 | 2 units: 5% saving |
| tirzepatide | Mounjaro KwikPen | 5mg/0.6ml | 1 pen (4 doses) | Self Injection | £189.99 | 2 units: 5% saving |
| tirzepatide | Mounjaro KwikPen | 7.5mg/0.6ml | 1 pen (4 doses) | Self Injection | £219.99 | 2 units: 5% saving |
| tirzepatide | Mounjaro KwikPen | 10mg/0.6ml | 1 pen (4 doses) | Self Injection | £239.99 | 2 units: 5% saving |
| tirzepatide | Mounjaro KwikPen | 12.5mg/0.6ml | 1 pen (4 doses) | Self Injection | £274.99 | 2 units: 5% saving |
| tirzepatide | Mounjaro KwikPen | 15mg/0.6ml | 1 pen (4 doses) | Self Injection | £284.99 | 2 units: 5% saving |